Dual mechanism of action of canagliflozin: excretion of glucose into the urine it is just the beginning of the story

• Alexander S. Ametov
• Prudnikova M.A.

Abstract

Canagliflozin is a highly selective inhibitor of the sodium dependent glucose co-transporter type 2 (SGLT2). SGLT2 inhibitors act to lower plasma glucose by lowering reabsorbtion of glucose filtered by the kidney. Canagliflozin is also a low potency SGLT1 inhibitor. Sodium dependent glucose co-transporter type 1 is mainly expressed in the intestine. This property of the drug leads to its beneficial effects on postprandial glycemia. We reviewed the practical aspects of treatment with canagliflozin based on the currently known properties of the drug.

Keywords:type 2 diabetes, canagliflozin, inhibitor of sodiumdependent glucose cotransporter 2

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)